Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lymphotactin-modified dendritic cells
- Development stage
- Preclinical
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Gene Therapies
- Administration
- Intradermal, Subcutaneous (ex Vivo Administration Of Modified Cells)
01
Overview
**Lymphotactin-modified dendritic cells** are dendritic cells (DCs) genetically engineered to express the chemokine lymphotactin (XCL1). This modification enhances the migratory ability of the DCs for CD4+ and CD8+ T cells, thereby boosting their capacity to induce antitumor immunity when loaded with antigenic peptides. In preclinical studies, these modified DCs have been shown to serve as more potent adjuvants for peptide delivery, inducing stronger cytotoxic T lymphocyte (CTL) responses and protective immunity against tumor challenges than unmodified dendritic cells[1][2][3]. The primary mechanism involves improved recruitment of antigen-specific T cells into the immune response due to secretion of lymphotactin, which acts via the chemokine receptor XCR1 principally expressed on cross-presenting dendritic cells[4][6]. This approach is under investigation as a cell therapy for cancer immunotherapy.
- Other names
- lymphotactin gene-modified dendritic cellsXCL1-modified dendritic cellsXCL-1-modified dendritic cellsXCL 1-modified dendritic cells
02
Targets
XCR1 (X-C motif chemokine receptor 1)
Beyond the preview
Go deeper on lymphotactin-modified dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lymphotactin-modified dendritic cells.